**Табела. 9.8** Компетентност ментора

|  |  |
| --- | --- |
| **Име и презиме** | [Небојша Павловић](https://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Pavlovic%20Nebojsa&samoar=#.YVyLQlVBzIU) |
| **Звање** | доцент |
| **Ужа научна, уметничка односно стручна област** | Фармацеутска технологија са индустријском фармацијом и козметологијом |
| **Академска каријера** | **Година** | **Институција** | **Ужа научна, уметничка односно стручна област** |
| Избор у звање | 2021. | Медицински факултет, Универзитет у Новом Саду | Фармацеутска технологија са индустријском фармацијом и козметологијом |
| Докторат | 2018. | Медицински факултет, Универзитет у Новом Саду | Медицинске науке - фармација |
| Специјализација |  |  |  |
| Магистратура |  |  |  |
| Мастер  |  |  |  |
| Диплома | 2010. | Медицински факултет, Универзитет у Новом Саду | Фармација |
| **Списак дисертација-докторских уметничких пројеката а у којима је наставнк ментор или је био ментор у претходних 10 година** |
| Р.Б. | Наслов дисертације- докторског уметничког пројекта  | Име кандидата | \*пријављена  | \*\* одбрањена |
|  |  |  |  |  |
| \*Година у којој је дисертација-докторски уметнички пројекат пријављена-пријављен (само за дисертације-докторске уметничке пројекте које су у току), \*\* Година у којој је дисертација-докторски уметнички пројекат одбрањена (само за дисертације-докторско уметничке пројекте из ранијег периода) |
| **Категоризација публикације научних радова из области датог студијског програма према класификацији ресорног Министарства просвете, науке и технолошког развоја а у складу са допунским захтевевима стандарда за дато поље** |
| **Р.б.** | **Публикација** | **ISI** | **M** | **IF** |
| 1. | Katanic J, Stanimirov B, Sekerus V, Djanic M, **Pavlovic N**, Mikov M, Stankov K. [Drug interference with biochemical laboratory tests](https://www.biochemia-medica.com/assets/images/upload/xml_tif/bm-33-2-020601.pdf). Biochem Med. 2023;33(2): 020601  | 10/29 (2022) | 22 (2022) | 3.3 (2022) |
| 2. | Milutinov J, Krstonošić V, Ćirin D, **Pavlović N**. [Emulgels: Promising Carrier Systems for Food Ingredients and Drugs](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223308/pdf/polymers-15-02302.pdf). Polymers (Basel). 2023 May 13;15(10):2302. | 16/86 (2022) | 21 (2022) | 5.0 (2022) |
| 3. | Ćirin D, **Pavlović N**, Nikolić I, Krstonošić V. [Assessment of Soy Protein Acid Hydrolysate-Xanthan Gum Mixtures on the Stability, Disperse and Rheological Properties of Oil-in-Water Emulsions](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10181046/pdf/polymers-15-02195.pdf). Polymers (Basel). 2023 May 5;15(9):2195. | 16/86 (2022) | 21 (2022) | 5.0 (2022) |
| 4. | Vukmirović S, Ilić V, Tadić V, Čapo I, **Pavlović N**, Tomas A, et al. [Comprehensive Analysis of Antioxidant and Hepatoprotective Properties of Morus nigra L](https://www.mdpi.com/2076-3921/12/2/382). Antioxidants (Basel). 2023 Feb 4;12(2):382. | 6/60(2022) | 21a(2022) | 7.0(2022) |
| 5. | Đanić M, **Pavlović N**, Lazarević S, Stanimirov B, Vukmirović S, Al-Salami H, et al. [Bioaccumulation and biotransformation of simvastatin in probiotic bacteria: A step towards better understanding of drug-bile acids-microbiome interactions](https://www.frontiersin.org/articles/10.3389/fphar.2023.1111115/full). Front Pharmacol. 2023 Feb 9;14:1111115. | 45/277(2022) | 21(2022) | 5.6(2022) |
| 6. | Mikov M, Đanić M, Lazarević S, **Pavlović N**, Stanimirov B, Al-Salami H, Mooranian A. [Editorial: Pharmacokinetic evaluation and modeling of clinically significant drug metabolites, Volume II](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846551/pdf/fphar-13-1087988.pdf). Front Pharmacol. 2023 Jan 4;13:1087988. | 45/277 (2022) | 21 (2022) | 5.6 (2022) |
| 7. | Vidović D, Milošević N, **Pavlović N**, Todorović N, Čanji Panić J, Kovačević S, Karadžić Banjac M, Podunavac-Kuzmanović S, Banjac N, Trišović N, Božić B, Lalić-Popović M. [Predicting percutaneous permeation for new succinimide derivatives by in vitro and in silico models](https://pdf.sciencedirectassets.com/271369/1-s2.0-S0022286022X00240/1-s2.0-S0022286022021615/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEF8aCXVzLWVhc3QtMSJHMEUCIQD6KVbtD5NR5kaRBGqiURAeIA2OxZJ6PsZOhqEcGX3xuQIgUobyT5ozCDbIRBaAdO98Gh%2BTi8xDElTz%2B5jit4p4%25). J Mol Struct. 2023;1274(2):134516. | 74/161 (2022) | 22 (2022) | 3.8 (2022) |
| 8. | **Pavlović N**, Milošević N, Đjanić M, Goločorbin-Kon S, Stanimirov B, Stankov K, Mikov M. Antimetastatic Potential of Quercetin Analogues with Improved Pharmacokinetic Profile: Pharmacoinformatic Preliminary Study. Anticancer Agents Med Chem. 2022;22(7):1407-13. doi: 10.2174/1871520621666210608102452. | 40/60 | 23 | 2.8 |
| 9. | Vidović D, Milošević N, **Pavlović N**, Todorović N, Panić JČ, Ćurčić J, Banjac N, Trišović N, Božić B, Lalić-Popović M. In silico-in vitro estimation of lipophilicity and permeability association for succinimide derivatives using chromatographic anisotropic systems and parallel artificial membrane permeability assay. Biomed Chromatogr. 2022 Sep;36(9):e5413. | 241/277 | 23 | 1.6 |
| 10. | Tomas Petrović A, **Pavlović N**, Stilinović N, Lalović N, Paut Kusturica M, Dugandžija T, Zaklan D, Horvat O. [Self-Medication Perceptions and Practice of Medical and Pharmacy Students in Serbia](file:///C%3A%5CUsers%5Cmilica.mircic%5CDownloads%5Cijerph-19-01193.pdf). Int J Environ Res Public Health. 2022;19(3):1193. | 81/302 (2021) | 21 (2021) | 4.614 (2021) |
| 11. | **Pavlović N**, Bogićević IA, Zaklan D, Đanić M, Goločorbin-Kon S, Al-Salami H, Mikov M. [Influence of Bile Acids in Hydrogel Pharmaceutical Formulations on Dissolution Rate and Permeation of Clindamycin Hydrochloride](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774652/pdf/gels-08-00035.pdf). Gels. 2022 Jan 5;8(1):35. | 18/86 | 21 | 4.6 |
| 12. | Tomas A, **Pavlović N**, Stilinović N, Horvat O, Paut-Kusturica M, Dugandžija T, Tomić Z, Sabo A. [Increase and change in the pattern of antibiotic use in Serbia (2010-2019)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067575/pdf/antibiotics-10-00397.pdf). Antibiotics (Basel). 2021;10(4):397. | 68/279 | 21 | 5.222 |
| 13. | Đanić M, **Pavlović N**, Stanimirov B, Lazarević S, Vukmirović S, Lazić J, Al-Salami H, Mikov M. [PAMPA model of gliclazide permeability: The impact of probiotic bacteria and bile acids](https://reader.elsevier.com/reader/sd/pii/S0928098720304565?token=175F3135E5253A4B9CA5D455363D571C58C3C0FE70FC7C68A7981A2A7F675C18DE798DFCDA2792981A7FA93629EEAF24&originRegion=eu-west-1&originCreation=20220810103043). Eur J Pharm Sci. 2021;158:105668.  | 74/279 | 21 | 5.112 |
| 14. | Jovičić-Bata J, **Pavlović N**, Milošević N, Gavarić N, Goločorbin-Kon S, Todorović N, Lalić-Popović M. [Coping with the burden of the COVID-19 pandemic: a cross-sectional study of community pharmacists from Serbia](https://bmchealthservres.biomedcentral.com/track/pdf/10.1186/s12913-021-06327-1.pdf). BMC Health Serv Res. 2021;21(1):304. | 63/109 | 22 | 2.908 |
| 15. | Milošević N, Milanović M, **Pavlović N**, Đurić L, Cacciola NA, Borrelli F, Milić N. [Indian ayurvedic herb, Boerhaavia diffusa as BCPR inhibitor: the story behind the curtains](https://reader.elsevier.com/reader/sd/pii/S0022286021016926?token=16FAF8EF60F0E21273E06E70B352CE1CE3C5DFFD5E1CE9B18409F1588DDD1A64E032BF1A57FB138ADDF013CD730DE10E&originRegion=eu-west-1&originCreation=20220810103434). J Mol Struct. 2021;1249:131564. | 82/163 | 22 | 3.841 |
| 16. | **Pavlović N**, Milošević N, Đanić M, Goločorbin-Kon S, Stanimirov B, Stankov K, Mikov M. Antimetastatic potential of quercetin analogues with improved pharmacokinetic profile: pharmacoinformatic preliminary study. Anticancer Agents Med Chem. 2022;22(7):1407-13. | 46/63(2021) | 23 (2021) | 2.527(2021) |
| 17. | Rajšić I, **Pavlović N**, Milijašević B, Vukmirović S, Spasić D, Žigić M, et al. [The increasing doses of methotrexate pharmacokinetics after intravenous administration in rats - model selection](http://www.doiserbia.nb.rs/img/doi/0042-8450/2021/0042-84501900126R.pdf). Vojnosanit Pregl. 2021;78(7):708-15. | 168/172 | 23 | 0.224 |
| 18. | Parezanović-Švonja G, Lalić-Popović M, Goločorbin-Kon S, Todorović N, **Pavlović N**, Mikov M. [In vitro comparative quality evaluation of non-expired and ten years expired lamotrigine immediate-release tablet formulations - pilot study.](http://dissolutiontech.com/issues/202002/DT202002_A02.pdf) Dissolut Technol. 2020;27:14-20. | 258/275 | 23 | 0.978 |
| 19. | Mikov M, **Pavlović N**, Stanimirov B, Djanić M, Goločorbin-Kon S, Stankov K, Al-Salami H. DPP-4 inhibitors: renoprotective potential and pharmacokinetics in type 2 diabetes mellitus patients with renal impairment. Eur J Drug Metab Pharmakokinet 2020;45(1):1-14. | 201/275 | 23 | 2.441 |
| 20. | Djanić M, Stanimirov B, **Pavlović N**, Vukmirović S, Lazić J, Al-Salami H, Mikov M. [Transport and biotransformation of gliclazide and the effect of deoxycholic acid in a probiotic bacteria model](https://www.frontiersin.org/articles/10.3389/fphar.2019.01083/full). Front Pharmacol. 2019;10:1083. | 52/270 | 21 | 4.225 |
| 21. | **Pavlović N**, Djanić M, Stanimirov B, Goločorbin-Kon S, Stankov K, Lalić-Popović M, Mikov M. In silico discovery of resveratrol analogues as potential agents in treatment of metabolic disorders. Curr Pharm Design 2019;35:3776-83. | 148/267 (2018) | 22 (2018) | 2.412 (2018) |
| 22. | **Pavlović N**, Goločorbin-Kon S, Ðanić M, Stanimirov B, Al-Salami H, Stankov K, Mikov M. [Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles](https://www.frontiersin.org/articles/10.3389/fphar.2018.01283/full). Front Pharmacol. 2018;9:1283. | 59/267 | 21 | 3.845 |
| 23. | Ðanić M, Stanimirov B, **Pavlović N**, Goločorbin-Kon S, Al-Salami H, Stankov K, Mikov M. [Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome](https://www.frontiersin.org/articles/10.3389/fphar.2018.01382/full). Front Pharmacol. 2018;9:1382. | 59/267 | 21 | 3.845 |
| 24. | Mikov M, Đanić M, **Pavlović N**, Stanimirov B, Goločorbin-Kon S, Stankov K, Al-Salami H. [Potential applications of gliclazide in treating type 1 diabetes mellitus: formulation with bile acids and probiotics](https://link.springer.com/article/10.1007/s13318-017-0441-y). Eur J Drug Metab Pharmacokinet. 2018;43(3):269-80. | 221/21 (2017) | 23 (2017) | 1.362 (2017) |
| 25. | **Pavlovic N**, Stanimirov B, Mikov M. Bile acids as novel pharmacological agents: the interplay between gene polymorphisms, epigenetic factors and drug response. Curr Pharm Des. 2017;23(1):187-215. | 74/255 (2015) | 21 (2015) | 3.052 (2015) |
| 26. | Mikov M, Đanić M, **Pavlović N**, Stanimirov B, Goločorbin-Kon S, Stankov K, Al-Salami H. [The role of drug metabolites in the inhibition of cytochrome P450 Enzymes](https://link.springer.com/article/10.1007/s13318-017-0417-y). Eur J Drug Metab Pharmacokinet. 2017;42(6):881-90. | 221/21 | 23 | 1.362 |
| 27. | Đanić M, **Pavlović N**, Stanimirov B, Vukmirović S, Nikolić K, Agbaba D,Mikov M. [The influence of bile salts on the distribution of simvastatin in the octanol/buffer system](https://www.researchgate.net/publication/280307444_The_influence_of_bile_salts_on_the_distribution_of_simvastatin_in_the_octanolbuffer_system). Drug Dev Ind Pharm. 2016;42(4):661-7. | 141/256 | 23 | 2.295 |
| 28. | Djanic M, **Pavlovic N**, Stanimirov B, Stojancevic T, Golocorbin-Kon S, Bojic G, Mikov M. [Docking-based preliminary study on the interactions of bile acids with drugs at the transporter level in intestinal bacteria](https://www.researchgate.net/profile/Maja_Danic_stojancevic/publication/295909947_Docking-based_preliminary_study_on_the_interactions_of_bile_acids_with_drugs_at_the_transporter_level_in_intestinal_bacteria/links/56d4376a08ae2ea08cf8e1d2/Docking-based-prel). Eur Rev Med Pharmacol Sci. 2016;20(3):553-60. | 180/256 | 23 | 1.778 |
| 29. | Raskovic A, **Pavlovic N**, Kvrgic M, Sudji J, Mitic G, Capo I, Mikov M. [Effects of pharmaceutical formulations containing thyme on carbon tetrachloride-induced liver injury in rats](http://download.springer.com/static/pdf/582/art%253A10.1186%252Fs12906-015-0966-z.pdf?originUrl=http%3A%2F%2Fbmccomplementalternmed.biomedcentral.com%2Farticle%2F10.1186%2Fs12906-015-0966-z&token2=exp=1496405050~acl=%2Fstatic%2Fpdf%2F582%2Fart%25253A10.118). BMC Complement Altern Med. 2015; 15(1):442. | 5/24 | 21 | 1.987 |
| 30. | Paut Kusturica M, Tomić Z, Bukumirić Z, Horvat O, **Pavlović N**, Mikov M, Sabo A. [Antibiotics in Serbian households: a source of potential health and environmental threats](http://apps.szu.cz/svi/cejph/archiv/2015-2-04-full.pdf)? Cent Eur J Public Health. 2015;23(2):114-8. | 242/260 | 23 | 0.525 |
| 31. | Raskovic A, Milanovic I, **Pavlovic N**, Milijasevic B, Ubavic M, Mikov M. [Analgesic effects of rosemary essential oil and its interactions with codeine and paracetamol in mice](http://www.europeanreview.org/wp/wp-content/uploads/165-172.pdf). Eur Rev Med Pharmacol Sci. 2015;19(1):165-72. | 186/255 | 23 | 1.575 |
| 32. | Raskovic A, Milanovic I, **Pavlovic N**, Cebovic T, Vukmirovic S, Mikov M. [Antioxidant activity of rosemary (Rosmarinus officinalis L.) essential oil and its hepatoprotective potential](https://bmccomplementalternmed.biomedcentral.com/track/pdf/10.1186/1472-6882-14-225?site=bmccomplementalternmed.biomedcentral.com). BMC Complem Altern M 2014;14:225. (9 p.). | 6/24 | 21 | 2.020 |
| 33. | Stilinović N, Škrbić B, Živančev J, Mrmoš N, **Pavlović N**, Vukmirović S. [The level of elements and antioxidant activity of commercial dietary supplement formulations based on edible mushrooms](http://pubs.rsc.org/en/content/articlepdf/2014/fo/c4fo00703d). Food & Function 2014;5(12):3170-8. | 17/122 | 21 | 2.791 |
| 34. | Stojančević M, **Pavlović N**, Goločorbin-Kon S, Mikov M. [Application of bile acids in drug formulation and deliver](http://www.tandfonline.com/doi/full/10.1080/21553769.2013.879925?scroll=top&needAccess=true)y. HFSP J. 2013;7(3-4):112-22. | 48/55 | 23 | 0.227 |
| **Збирни подаци научне активност наставника** |
| **Збирни подаци уметничке активност наставника** |
| Укупан број цитата, без аутоцитата | **864** (Scopus) |
| Укупан број радова са SCI (или SSCI) листе | **36** |
| Тренутно учешће на пројектима | Домаћи **2** | Међународни **1** |
| Усавршавања | - Фармацеутски факултет, Curtin Универзитет, Перт, Аустралија; 9. септембар - 10. новембар 2017. у оквиру HORIZON 2020 пројекта (No. 690876)- Seminar on Pharmaceutical & Medical Investment and Cooperation for Developing Countries, организатор: Sinopharm Intl., 20. јул - 9. август 2016., Пекинг, Кина |
| Други подаци које сматрате релевантним | - Награда „Др Зоран Ђинђић“ (треће место) за најбоље истраживаче у АП Војводина у 2019. години- Руководилац пројекта, програм Покрени се за науку, Центар за развој лидерства и компанија Филип Морис (2019-2020) |

Максимална дужине не сме бити већа од 2 странице А4